Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1053)	7/27/1998 9:46:00 PM
From: BMcV	Read Replies (2) \| Respond to of 10280

Ed, 100 by year-end seems very aggressive to me, don't you think?. On the other hand, SEPR is entering that sweet sixteen time of a biotech's life, where tangible results are close at hand yet still not real, so our fantasies seem realizable and as yet have no blemishes. So maybe SEPR will have a huge run in here. Agouron did, before they started selling anything, and the stock has never returned to those old highs. Biogen also did very well before bringing their blockbuster to market, then spent most of '97 languishing as everybody wrung their hands worrying about patents, competition, side effects, what's in the pipeline. Of course, the pipeline at least is no worry for SEPR. Anyway, my head's still spinning from 50! Bruce